H19 Expression in Hepatic Metastases from a Range of Human Carcinomas

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2005 Sep 29

PMID 16189152

Citations 41

Authors

Y Fellig

I Ariel

P Ohana

P Schachter

I Sinelnikov

T Birman

S Ayesh

T Schneider

N De Groot

A Czerniak

A Hochberg

Affiliations

Soon will be listed here.

Abstract

Aims: To investigate the expression of the imprinted oncofetal H19 gene in hepatic metastases derived from a range of human carcinomas and assess its prognostic value with the view of developing a DNA based treatment for such metastases.

Methods: Non-radioactive in situ hybridisation for H19 RNA was performed on paraffin wax embedded sections of liver biopsies or partial hepatectomy specimens, taken from 80 patients with hepatic metastases derived from carcinomas from several medical centres in Israel. The degree of expression was graded qualitatively according to the number of cells expressing H19 and the intensity of staining. The medical files were searched for demographic data and survival times before and after diagnosis of hepatic metastases.

Results: H19 expression was found in the hepatic metastases of 64 of 80 patients. High expression (higher staining grades) of H19 in the metastases was found in 43 of 80 patients. However, H19 expression status in the hepatic metastases did not correlate with either the length of time to development of metastasis or overall survival.

Conclusions: H19 is highly expressed in more than half of hepatic metastases derived from a range of carcinomas. Thus, these metastases may be suitable candidates for H19 DNA based treatment. Further studies are needed to determine whether H19 expression has prognostic value in metastatic liver disease using larger numbers of specific subtypes of primary carcinomas.

Citing Articles

Long non-coding RNA H19 promotes proliferation in hepatocellular carcinoma cells via H19/miR-107/CDK6 axis.

Nokkeaw A, Thamjamrassri P, Chantaravisoot N, Tangkijvanich P, Ariyachet C Oncol Res. 2023; 31(6):989-1005.

PMID: 37744274 PMC: 10513943. DOI: 10.32604/or.2023.030395.

Long non-coding RNA signature in colorectal cancer: research progression and clinical application.

Wu Y, Xu X Cancer Cell Int. 2023; 23(1):28.

PMID: 36797749 PMC: 9936661. DOI: 10.1186/s12935-023-02867-0.

Long non-coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors.

Zhang R, Zeng Y, Deng J Clin Exp Med. 2022; 23(5):1425-1440.

PMID: 36484927 DOI: 10.1007/s10238-022-00947-5.

Obtaining Reliable RT-qPCR Results in Molecular Diagnostics-MIQE Goals and Pitfalls for Transcriptional Biomarker Discovery.

Gratz C, Bui M, Thaqi G, Kirchner B, Loewe R, Pfaffl M Life (Basel). 2022; 12(3).

PMID: 35330136 PMC: 8953338. DOI: 10.3390/life12030386.

Long Non-coding RNA Signature for Liver Metastasis of Colorectal Cancers.

Liu F, Song Z, Wang X, Du S, Peng N, Zhou J Front Cell Dev Biol. 2021; 9:707115.

PMID: 34307387 PMC: 8297503. DOI: 10.3389/fcell.2021.707115.

References

Lynch C, Tycko B, Bestor T, Walsh C . Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation. Mol Cancer. 2002; 1:2. PMC: 119368. View

Bonetti A . Hepatic artery infusion for liver metastases from colorectal cancer. Lancet. 2003; 361(9355):358-9. DOI: 10.1016/S0140-6736(03)12439-7. View

Ariel I, Lustig O, OYER C, Elkin M, Gonik B, Rachmilewitz J . Relaxation of imprinting in trophoblastic disease. Gynecol Oncol. 1994; 53(2):212-9. DOI: 10.1006/gyno.1994.1118. View

Ariel I, Sughayer M, Fellig Y, Pizov G, Ayesh S, Podeh D . The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol. 2001; 53(6):320-3. PMC: 1186987. DOI: 10.1136/mp.53.6.320. View

Erce C, Parks R . Interstitial ablative techniques for hepatic tumours. Br J Surg. 2003; 90(3):272-89. DOI: 10.1002/bjs.4091. View

Tanos V, Prus D, Ayesh S, Weinstein D, Tykocinski M, de-Groot N . Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999; 85(1):7-11. DOI: 10.1016/s0301-2115(98)00275-9. View

Kanduri C, Kanduri M, Liu L, Thakur N, Pfeifer S, Ohlsson R . The kinetics of deregulation of expression by de novo methylation of the h19 imprinting control region in cancer cells. Cancer Res. 2002; 62(16):4545-8. View

Vernucci M, Cerrato F, Pedone P, Dandolo L, Bruni C, Riccio A . Developmentally regulated functions of the H19 differentially methylated domain. Hum Mol Genet. 2003; 13(3):353-61. DOI: 10.1093/hmg/ddh028. View

Ariel I, Miao H, Ji X, Schneider T, Roll D, De Groot N . Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol. 1998; 51(1):21-5. PMC: 395603. DOI: 10.1136/mp.51.1.21. View

10.

Ayesh B, Matouk I, Ohana P, Sughayer M, Birman T, Ayesh S . Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther. 2003; 7(4):535-41. DOI: 10.1016/s1525-0016(03)00056-x. View

11.

Tanos V, Ariel I, Prus D, de-Groot N, Hochberg A . H19 and IGF2 gene expression in human normal, hyperplastic, and malignant endometrium. Int J Gynecol Cancer. 2004; 14(3):521-5. DOI: 10.1111/j.1048-891x.2004.014314.x. View

12.

Lustig-Yariv O, Schulze E, Komitowski D, Erdmann V, Schneider T, De Groot N . The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene?. Oncogene. 1997; 15(2):169-77. DOI: 10.1038/sj.onc.1201175. View

13.

Lottin S, Adriaenssens E, Dupressoir T, Berteaux N, Montpellier C, Coll J . Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis. 2002; 23(11):1885-95. DOI: 10.1093/carcin/23.11.1885. View

14.

Ohana P, Bibi O, Matouk I, Levy C, Birman T, Ariel I . Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer. 2002; 98(5):645-50. DOI: 10.1002/ijc.10243. View

15.

Taniguchi T, Sullivan M, Ogawa O, Reeve A . Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. Proc Natl Acad Sci U S A. 1995; 92(6):2159-63. PMC: 42443. DOI: 10.1073/pnas.92.6.2159. View

16.

Ayesh S, Matouk I, Schneider T, Ohana P, Laster M, de-Groot N . Possible physiological role of H19 RNA. Mol Carcinog. 2002; 35(2):63-74. DOI: 10.1002/mc.10075. View

17.

Allendorf J, Ippagunta N, Emond J . Management of liver metastases: new horizons for biologically based therapy. J Surg Res. 2004; 117(1):144-53. DOI: 10.1016/j.jss.2003.11.003. View

18.

Verkerk A, Ariel I, Dekker M, Schneider T, Van Gurp R, De Groot N . Unique expression patterns of H19 in human testicular cancers of different etiology. Oncogene. 1997; 14(1):95-107. DOI: 10.1038/sj.onc.1200802. View

19.

Elias D, Maisonnette F, Druet-Cabanac M, Ouellet J, Guinebretiere J, Spielmann M . An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg. 2003; 185(2):158-64. DOI: 10.1016/s0002-9610(02)01204-7. View

20.

Ng A, Tang J, Goh C, Hui K . Regulation of the H19 imprinting gene expression in human nasopharyngeal carcinoma by methylation. Int J Cancer. 2003; 104(2):179-87. DOI: 10.1002/ijc.10926. View